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MICHAEL J. MALINOWSKI* AND RADHIKA RAO*
Legal Limitations on Genetic Research and the
Commercialization of its Results
The United States continues to pursue the commercial applica-
tion of biotechnology with passion and aggression.' The pharmaceu-
tical and biotechnology sectors reported a $49.3 billion investment in
research and development (R&D) in human health products in 2004
and, among the multiple conduits for federal government investment
in biomedical research, the operating budget of the National Insti-
tutes of Health (NIH) alone was $28 billion that year.2 With a map of
the human genome in hand,3 making medical sense out of that map is
an ongoing endeavor undertaken by the U.S. government, academia,
and the private sector, often in collaboration.4
* J.D. Yale Law School 1991; B.A., summa cum laude, Tufts University 1987.
Ernest R. and Iris M. Eldred Endowed Professor of Law, Paul M. Hebert Law Center,
Louisiana State University (LSU), and Co-Founder and Associate Director, Program
in Law, Science, and Public Health.
* J.D. Harvard Law School magna cum laude 1990; A.B. Physics and Chemistry
Harvard College 1986. Professor of Law, University of California, Hastings College of
the Law.
1. See generally PHRMA, PHARMACEUTICAL INDUSTRY PROFILE 2005 (2005) ["PRO-
FILE"], available at www.phrma.org.
2. See id. at pp. 2-6; National Institutes of Health, Summary of the FY2006 Pres-
ident's Budget (2005), http://www.nih.gov/about/director/budgetrequest/index.htm.
Jonathan Weisman, 2006 Cuts in Domestic Spending on Table, WASH. POST, May
27, 2004, at A01, available at 2004 WL 74490860; Drug Development; Medicine Price
Hike Highlights Controversy of Government Funding Drug Research, MED. LETTER
ON CDC & FDA 27 (June 20, 2004), 2004 WL 55170701 (no author identified). 2005
industry data is not available at this time.
3. HGP was driven to completion years ahead of schedule through competition
between industry and government-led teams that ultimately joined forces to declare a
joint victory. See generally 291 SCIENCE 1145 (Feb. 16, 2001) (issue entitled "The
Human Genome"); 409 NATURE 745 (Feb. 15, 2001) (issue Information about the
Human Genome Project dedicated to the release of a draft map of the human genome).
Information about HGP may be obtained from the National Human Genome Research
Institute (NHGRI) at www.nhgri.nih.gov.
4. PROFILE, supra note 1, at 8-14. See generally U.S. Senate, Joint Economic
Committee, The Benefits of Medical Research and the Role of the NIH (May 2000)
(examining the role of federal funding for medical research and derivative benefits);
GENERAL ACCOUNTING OFFICE, REPORT TO CONGRESSIONAL COMMITTEES: TECHNOLOGY
TRANSFER, ADMINISTRATION OF THE BAYH-DOLE ACT By RESEARCH UNIvERsITIEs, GAO/
RCED-98-126 (May 1998), available at www.access.gpo.gov; DEP'T HEALTH & HUMAN
SERVS., NATL INST. OF HEALTH, NIH RESPONSE TO THE CONFERENCE REPORT REQUEST
FOR A PLAN TO ENSURE TAXPAYERS' INTERESTS ARE PROTECTED (July 2001), available at
http://www.nih.gov/news/070101wyden.htm; National Institutes of Health, Office of
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The maturation of biotechnology as applied science is transform-
ing industry and at least beginning to have a meaningful impact on
the delivery of health care.5 As recognized by the pharmaceutical in-
dustry, "the convergence of traditional pharmaceutical chemistry and
biotechnology has led to the pharmaceutical and biotechnology indus-
tries, once thought of as being distinct and independent, [becoming]
more similar than dissimilar."6 After decades of dependence upon
pharmaceuticals to treat human health needs, the emerging genera-
tion of medicines are biopharmaceuticals. 7 The integration of biotech
application and the delivery of health care is adding a new dimension
of complexity to familiar pressing issues such as health care finance,
and also introducing significant changes to the fundamentals of
health care delivery and the human medicinal product markets.8 For
example, developing pharmaceuticals around alleles (genetic varia-
tions) is resulting in much more precision, and large disease group-
ings such as "breast cancer" are being broken down into BRCAI/
BRCA2-associated breast cancer, Her-2-neu-associated breast cancer,
and other genetic-based sub-classifications.9 Genetic profiling capa-
bilities are expanding immensely, both as a by-product of bi-
opharmaceutical R&D centered on genomics and its cousin
disciplines10 and through efforts such as the SNPs Consortium-a
collaboration to identify genetic subtleties that have medical mean-
ing, such as an individual patient's reaction to commercial
pharmaceuticals.11
Technology Transfer, NIH Technologies in the Development of Drugs, Diagnostics,
and Research Tools (2003), http://ott.od.nih.gov/newpages/techdev.pdf.
5. For identification of biotech medicines and vaccines brought to market, see
Biotechnology & Health Care, available at www.bio.org (official Internet site of the
world's largest biotechnology trade organization). Biotechnology also has been used
to develop medical devices and other human health products, including tissue prod-
ucts, I \that impact human health directly. Information about these products is avail-
able at the official web site of the Food and Drug Administration, www.fda.gov. More
than 320 biotech drugs and vaccines are now in clinical trials. See generally PHARMA-
CEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, MEDICINES IN DEVELOPMENT:
BIOTECHNOLOGY (Oct. 2004).
6. PROFILE, supra note 1, at vi.
7. Id. For identification of biotech medicinal products, visit www.bio.org. (the
official web site of the Biotechnology Industry Organization).
8. See generally A.E. Guttmacher, F.S. Collins, Welcome to the Genomic Era,
NEW ENGLAND J. MED. 349 (2004): 996-98, available at www.nejm.org. See also L.
Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients'
Genetic Profiles, 43 JURIMETRICS: THE JOURNAL OF LAW, SCIENCE, AND TECHNOLOGY 1,
4-11 (2002); Michael J. Malinowski, Law, Policy, and Market Implications of Genetic
Profiling in Drug Development, 2 H. J. OF HEALTH LAW & POL'Y 31-63, 31-43 (2003).
9. The Baylor College of Medicine has established online-searching capabilities
for breast cancer genes. See Baylor College of Medicine, Breast Cancer Gene
Database, at http://condor.bcm.tmc.edu/ermb/bcgd/bcgd.html.
10. For example, genetic profiling is being utilized to tailor human clinical tri-
als-a field known as pharmacogenomics. See generally supra note 8.
11. Complementary fields are pharmacogenomics (research centered on the ex-
pression of alleles shared by groups) and pharmacogenetics (tailoring of health care
46 [Vol. 54
LEGAL LIMITATIONS ON GENETIC RESEARCH
This Report focuses on several issues presently at the epicenter
of biotechnology-related controversy in science, medicine, and law-
policy within the U.S. The Report is organized along the R&D contin-
uum spanning from basic research to medicinal and commercial ap-
plications. 12 Parts I through III address priority issues in basic
research at this time: gene patents, human cloning and stem cell re-
search, and population genetics, respectively. Part III includes dis-
cussion of the International Haplotype Mapping Project and
Consortium (HapMap Project) presently underway through the Na-
tional Institutes of Health (NIH), National Human Genome Research
Institute (NHGRI).13 Part IV addresses the impact of applied bio-
technology on assisted reproduction, a burgeoning commercial sector
in the U.S.' 4 Part V explores the extent to which the challenges
before and controversies being experienced by the "gatekeeper" to the
U.S. biopharmaceutical market, the Food and Drug Administration
(FDA), may impact biotechnology R&D and the biopharmaceutical
markets. Part VI addresses the nexus between the health care fi-
nance dilemma in the U.S. and commercial biotechnology. The Re-
port concludes that the U.S., the primary incendiary of the "genomics
revolution," has made a multifaceted-governmental, commercial,
and health care-commitment to biotechnology, and that loyalty re-
mains strong as the U.S. grapples with associated law-policy com-
plexities, both in basic research and health care applications.
I. GENE PATENTS
Now that the map of the human genome is complete, much of the
genetic code has already been claimed for private ownership. Compa-
nies and universities have obtained patents on more than 4,000
human genes, almost 20 percent of the roughly 24,000 human
genes. 15 Whether human genes should be patentable is hotly con-
tested. Some oppose the patenting of human genes on moral
grounds, arguing that human beings should not be the subject of
and biopharmaceuticals to individual genetic profiles). See generally Malinowski, Ge-
netic Profiling, supra note 8; Noah, Pharmacogenomics, supra note 8.
12. This organization reflects that utilized by one of the authors in his treatise on
biotechnology R&D, BIOTECHNOLOGY: LAW BUSINESS, AND REGULATION (Aspen 1999 &
supps., 2000-2004).
13. Official sites with information about the HapMap Project are www.hapmap.
org and www.genome.gov.
14. See Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our
Eugenics Past-Present, and Future?, 36 CONN. L. REV. 125, 179-97 (2003). Cf. PRESI-
DENT'S COUNCIL ON BIOETHICS, REPRODUCTION AND RESPONSIBILITY: THE REGULATION
OF NEW BIOTECHNOLOGIES 54-63 (2004), available at http://www.bioethics.gov/reports/
reproductionandresponsibilityLpcbefinal-reproduction andresponsibility.pdf.
15. Stefan Lovgren, One-Fifth of Human Genes Have Been Patented, Study
Reveals, National Geographic News, October 13, 2005.
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property rights.16 Others object that DNA sequences should not be
patentable because they are discoveries of nature that are the com-
mon heritage of all, rather than man-made inventions.' 7
Nevertheless, current U.S. policy as set by Congress, the Patent
and Trademark Office (PTO), and the federal courts permits patents
on human genes. As explained by a former director of the PTO:
"From a patent law standpoint, genes are treated just like any other
chemical found in nature."18 The U.S. Constitution grants Congress
the exclusive power "[to promote the Progress of Science and useful
Arts, by securing for limited Times to Authors and Inventors the ex-
clusive Right to their respective Writings and Discoveries."19 Con-
gress has implemented this power by enacting a group of statutes
known as the Patent Act, 2 0 which authorize patents to be issued if
the subject matter of the invention is patentable, i.e., a "process, ma-
chine, manufacture, or composition of matter,"2 1 and if the invention
is "useful,"22 "novel," 23 "non-obvious," 24 and "adequately enabled and
described." 25
Patents can be issued for "anything under the sun that is made
by man," but not for "laws of nature, physical phenomena, and ab-
stract ideas."26 Thus, in Diamond v. Chakrabarty, the Supreme
Court allowed a genetically-engineered living microorganism to be
patented because it was the product of human ingenuity.27 While
newly-discovered plants, minerals, and other natural phenomena
cannot be patented because they exist without human intervention, 28
16. See, e.g., Gail E. Bundy, Letter to Commissioner of Patents and Trademarks,
Comment 2, Public Comments on the United States Patent and Trademark Office,
Revised Interim Utility Examination Guidelines, 64 FR 71440, Dec. 21, 1999, cor-
rected 65 FR 3425, Jan. 21, 2000, available at http://www.uspto.gov/web/offices/com/
sol/comments/utilguide/index.html (arguing that the PTO lacks authority to grant
patents on human genes because they are part of life, and all life is sacred).
17. See, e.g., Debra Harry, Letter to Commissioner of Patents and Trademarks,
Indigenous Peoples Council on Biocolonialism, Comment 39, Public Comments on the
United States Patent and Trademark Office, Revised Interim Utility Examination
Guidelines, 64 FR 71440, Dec. 21, 1999, corrected 65 FR 3425, Jan. 21, 2000, available
at http://www.uspto.gov/web/offices/com/sol/comments/utilguide/index.html (contend-
ing that human genes are not patentable because they are products of nature, not
inventions).
18. Andrew Pollack, Patenting a Human Gene As if It Were an Invention, N.Y.
TIMES, June 28, 2000, at C1.
19. U.S. Const. Art. I., Sec. 8, Cl. 8.
20. 35 U.S.C. §§1 et seq.
21. 35 U.S.C. §101.
22. 35 U.S.C. §101.
23. 35 U.S.C. §102.
24. 35 U.S.C. §103.
25. 35 U.S.C. § 112.
26. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
27. See id. at 309-310.
28. See Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948) (finding
a new combination of bacteria to be "no more than the discovery of some of the handi-
work of nature and hence . .. not patentable").
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isolated and purified versions of naturally occurring substances are
patentable. 29 Gene patents lie at the intersection of these two lines of
precedent because they involve isolated and purified DNA sequences
from living organisms. In upholding a gene patent, one federal court
reasoned: "The invention claimed in the patent is not . .. the DNA
sequence encoding human EPO since that is a nonpatentable natural
phenomenon 'free to all men and reserved exclusively to none. . . .'
Rather, the invention as claimed . .. is the 'purified and isolated'
DNA sequence encoding erythropoietin."30
A gene patent grants what is essentially a monopoly over the
gene for 20 years, giving its owner the power to prevent others from
conducting research, performing tests, or developing therapies for
that gene without obtaining a license and paying royalties. As a re-
sult, gene patents may actually hinder innovation31 and impede the
delivery of health care services. 32 For these reasons, gene patents
have been the subject of much criticism, although a study published
in Science in March 2005 suggests that the problem is not the theory
but the practice of the PTO in approving too many flawed gene pat-
ents. After examining 74 human gene patents, the study concludes
that almost three-fourths of these patents contain at least one "prob-
lematic" claim, that is, a claim that fails to satisfy the legal require-
ments for a patent.3 3
Moreover, unlike many other countries, the U.S. has no explicit
research exception to its patent laws that would allow basic research
using patented genes to proceed without obtaining permission from
the patent holder.34 There is a statutory exemption for use of a pat-
ented invention that is "reasonably related to the development and
submission of information under a Federal law which regulates the
29. See Parke-Davis & Co. v. H.K Mulford Co., 189 F.95 (S.D.N.Y. 1911) (uphold-
ing a patent on an isolated and purified version of adrenalin that had been extracted
from the glands of animals).
30. Amgen Inc. v. Chugai Pharmaceutical Co., Ltd., 1989 U.S. Dist. LEXIS 16110,
*88-89 (D. Mass., December 11, 1989), affirmed in relevant part, 927 F.2d 1200 (Fed.
Cir. 1991), cert. denied, 502 U.S. 856 (1991).
31. See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation?
The Anticommons in Biomedical Research, SCIENCE, May 1, 1998, at 698 (explaining
how patents may deter innovation in biomedical research: "A proliferation of intellec-
tual property rights upstream may be stifling life-saving innovations further down-
stream in the course of research and product development.").
32. See Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial In-
centives with Health Needs, 2002 Hous. J. HEALTH L. & POL'Y 65, 89 (2002).
33. Jordan Paradise, Lori Andrews, Timothy Holbrook, Patents on Human Genes:
An Analysis of Scope and Claims, 307 SCIENCE 1566 (Mar. 11, 2005). See also Bad
Gene Patents, THE ECONOMIST, Mar. 12, 2005.
34. See Lori Andrews, supra note 32, at 86. See also Rebecca S. Eisenberg, Pat-
ents and the Progress of Science: Exclusive Rights and Experimental Use, 56 U. CHI. L.
REv. 1017, 1018-1019 n. 6 (1989) (describing European research exception to patent
law); Janice M. Mueller, No "Dilettante Affair": Rethinking the Experimental Use Ex-
ception to Patent Infringement for Biomedical Research Tools, 76 WASH. L. REv. 1, 39
(2001) (describing Japan's experimental use exception).
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manufacture, use, or sale of drugs."35 However, the Supreme Court
recently interpreted this exemption to exclude "[iblasic scientific re-
search . . . performed without the intent to develop a particular
drug."36 And the common law research exception has been construed
extremely narrowly by the Federal Circuit to apply only to research
that is "solely for amusement, to satisfy idle curiosity, or for strictly
philosophical inquiry."37 Even research with no commercial applica-
tions performed in a university setting does not qualify for this excep-
tion because it furthers the university's "legitimate business
objectives" by increasing the status of the institution and attracting
research grants, students, and faculty.38
II. HUMAN CLONING AND STEM CELL RESEARCH
In 1996, Ian Wilmut succeeded in cloning the famous lamb
Dolly, 3 9 spurring scientists to use the same technique to clone many
other animals, including cows, 4 0 mice, 41 horses,42 and dogs.43 There
have even been attempts to clone human beings, with ACT (Ad-
vanced Cell Technology), a small company in Boston, reporting that it
had cloned human embryos in October 2001,44 and rumors of the
birth of a cloned human child floating around in December 2002.45
More recently, scientists have touted the promise of embryonic stem
cells for medicine and South Korean researchers claimed that they
actually managed to clone human embryos for the purpose of harvest-
ing stem cells.4 6 Also, a team of Harvard scientists announced a rev-
35. 35 U.S.C. §271(e)(1).
36. See Merck v. Integra Lifesciences, 125 S. Ct. 2372, 2382-2383 (2005) (holding
that the statutory exemption applies only if there is a "reasonable basis" for believing
that use of the patented compound in research, if successful, would be appropriate to
include in a submission to the FDA, even if the patented compound is used (1) in
experiments on drugs that are not ultimately submitted to the FDA or (2) in experi-
ments that are not ultimately submitted to the FDA).
37. Madey v. Duke University, 307 F.3d 1351, 1362 (Fed. Cir. 2002).
38. Id. at 1362.
39. Michael Specter, A New Creation: The Path to Cloning, N.Y. TIMES, Mar. 3,
1997, at Al.
40. Gina Kolata, Holstein Calves Cloned From Cells, Paper Says, N.Y. TIMES, May
23, 1998, at All.
41. Gina Kolata, In Big Advance, Cloning Creates Dozens of Mice, N.Y. TIMES,
July 23, 1998, at Al.
42. Gareth Cook, Scientists in Italy Clone Horse, BOSTON GLOBE, Aug. 7, 2003, at
Al.
43. Rowan Hooper, First Canine Clone Is a Chip Off the Old Block, NEW SCIEN-
TIST, Aug. 6, 2005, at 15.
44. Gina Kolata, A Breakthrough On Cloning?, N.Y. TIMES, Nov. 27, 2001, at Al.
For information about Advanced Cell and its research, visit the company Internet site
at http://www.advancecell.com.
45. Linda Greenhouse, FDA Exploring Human Cloning Claim, N.Y. TIMES, Dec.
30, 2002, at A10.
46. James Brooke, Without Apology, Leaping Ahead in Cloning, N.Y. TIMES, May
31, 2005, at Fl. Dr. Hwang Woo Suk, the principal South Korean researcher, received
world acclaim as the first person to successfully clone a human embryo and extract
50 [Vol. 54
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olutionary new cell fusion technique which may generate stem cells
with less controversy. 47
Much of the debate surrounding genetic research in the U.S. has
focused on the twin issues of human cloning and the production of
stem cells from human embryos, 48 perhaps because of a perceived
link to the controversial topic of abortion. Of the two issues, human
embryonic stem cell research (HESCR) has received the most public-
ity. On August 9, 2001, President George W. Bush addressed the na-
tion on this topic, declaring a ban on federal funding for any research
involving human embryonic stem cells that were created after that
date.49 This action severely limited the scope of federally-funded re-
search on human embryonic stem cells to the small number of cell
lines already in existence at the time of the President's announce-
ment. Moreover, HESCR has itself become a potent political issue, as
is evident in the fact that Ronald Reagan Jr., son of the venerated
Republican President, crossed party lines to make a dramatic appear-
ance at the Democratic Convention, emphasizing the importance of
allowing such research.50 Indeed, an unofficial commission of 80
Nobel prizewinners even wrote a letter to President George W. Bush
expressing their strong support for federal funding for stem research,
citing the promise of "novel therapies for a range of serious and cur-
rently intractable issues."51
Apart from the ban on federally-funded HESCR, there are no fed-
eral laws that specifically limit human cloning or stem cell research
as of December 2005. To the contrary, some states are actively pro-
stem cells from it. In November 2005, however, Dr. Hwang acknowledged that he lied
over the sources of human eggs used in his work and stepped down as Director of a
new research center. See James Brooke, Korean Leaves Cloning Center in Ethics Fu-
ror, N.Y. TIMEs, Nov. 25, 2005, at Al, A8. Some eggs were donated by his junior
researchers, while others were drawn from about 20 women who were paid for their
eggs. See id. And in December 2005, Dr. Hwang admitted that he had fabricated
some of his research, raising doubts regarding the feasibility of creating stem cells
from cloned human embryos. See Nicholas Wade, Korean Scientist Said to Admit
Fabrication in a Cloning Study, N.Y. TIMES, Dec.16, 2005, at Al, A6.
47. Gareth Cook & Carey Goldberg, Harvard Scientists Advance Cell Work: Tech-
nique Doesn't Destroy Embryos, Boston Globe, August 22, 2005. After fusing an adult
human skin cell with an existing embryonic stem cell, the Harvard scientists found
that the resulting hybrid looked and acted like an embryonic stem cell. This tech-
nique may eventually make it possible to obtain genetically-matched embryonic stem
cells for use in medical therapy using existing cell lines, without the need to create
and destroy cloned human embryos. See id.
48. Rick Klein, GOP Leader Looks For a Stem Cell Avenue, BOSTON GLOBE, Jul.
13, 2005, at A3.
49. Press Release, The White House, Office of the Press Secretary, Remarks by
the President on Stem Cell Research (Aug. 9, 2001), available at http://www.
whitehouse.gov/news/releases/2001/08/20010809-2.html); see also, Aaron Zitner, Bush
OKs Limited Stem Cell Funding, L.A. TIMES, Aug. 10, 2001, at Al.
50. Robin Toner, On 2nd Night, Unity Is Theme For Democrats, N.Y. TIMES, Jul.
28, 2004, at Al.
51. Gretchen Vogel, Nobel Laureates Lobby for Stem Cells, SCIENCE, Mar. 2, 2001,
Vol. 291, at 1683.
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moting such research. For example, California voters recently ap-
proved Proposition 71, which devotes the unprecedented sum of $3
billion of public money to fund stem cell research. 52 Other states
seem to be following suit, seeking to encourage stem cell research,
albeit without allocating such large amounts of public money.53
However, many states have enacted laws that ban human reproduc-
tive cloning,54 while some states also prohibit non-reproductive clon-
ing, effectively preventing certain forms of stem cell research.55
Moreover, both human cloning and embryonic stem cell research are
subject to a patchwork of general federal regulations, such as those
governing research upon human subjects, and any clinical applica-
tions of such research would obviously require FDA approval.56
The dearth of federal regulation has prompted scientists to pro-
pose a system of self-regulation. Thus the National Academy of Sci-
ences, a self-selected group of scientists that advises the government,
issued a comprehensive set of guidelines for HESCR in April 2005, in
the hope that these limits would be voluntarily adopted by all institu-
tions engaged in such research.57 The guidelines call for the estab-
lishment of a national commission, as well as local committees (called
Embryonic Stem Cell Research Oversight or ESCRO committees) to
oversee such research. They require the informed consent of all per-
sons who donate eggs, sperm, embryos, or other genetic material and
prohibit the payment of donors.58 They recommend that certain
forms of embryonic stem cell research be prohibited, including re-
52. California Stem Cell Research and Cures Act (Proposition 71), adopted by vot-
ers at the 2004 general election, effective Nov. 3, 2004, as codified in Ch. 3 of the
California Health & Safety Code. Proposition 71 has been challenged on state consti-
tutional law grounds by several organizations, including the California Family
Bioethics Council, the People's Advocate, and the National Tax Limitation Founda-
tion. Alameda County Superior Court Judge Bonnie Lewman Sabraw declined to dis-
miss the lawsuits, which are scheduled to go to trial on Feb. 27, 2006. See Megan
Garvey, Stem Cell Lawsuits Survive Challenge, L.A. TIMES, Nov. 30, 2005; Judge Has
Crucial Role in Future of Stem Cell Research, SACRAMENTO BEE, Dec. 8, 2005.
53. Tina Kelly, In Race Toward First Stem Cell Research Institute, New Jersey
Stalls, N.Y. TIMES, July 31, 2005, at 25; see also Betsy Morris, Fighting for Their
Lives, FORTUNE, Aug. 22, 2005, at 48. New Jersey and eight other states are in vari-
ous stages of the legislative and initiative process.
54. States that prohibit only reproductive cloning include California, Connecticut,
Massachusetts, New Jersey, and Rhode Island. See The National Academies, Guide-
lines for Human Embryonic Stem Cell Research, National Academy Press, Apr. 26,
2005, at 75. (see http:/ /books.nap.edu/catalog/11278.html?onpinewsdocO262005
[hereinafter "NAS Report"].
55. States that proscribe both reproductive and research cloning include Arkan-
sas, Indiana, Iowa, Michigan, North Dakota, and South Dakota. See NAS Report,
supra note 54, at 75.
56. See NAS Report, supra note 54, at 3.
57. See generally id. See also Nicholas Wade, Scientists Draft Rules on Ethics For
Stem Cells, N.Y. TIMES, Apr. 27, 2005, at All; The National Academies, Guidelines
for Human Embryonic Stem Cell Research, National Academy Press, Apr. 26, 2005
(see http://www4.nationalacademies.org/news.nsf/isbn/0309096537?OpenDocument).
58. See NAS Report, supra note 54, at 101.
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search upon a human embryo for longer than 14 days, beyond devel-
opment of the primitive streak, and research in which human
embryonic stem cells are introduced into human blastocysts or non-
human primate blastocysts.5 9 The guidelines also provide that ani-
mals into which human embryonic stem cells have been introduced
should not be allowed to breed.60
When stem cell research is disentangled from the issue of human
cloning, it appears to have widespread support.61 Thus the House of
Representatives, in a bipartisan effort, passed House Resolution 810,
the Stem Cell Research Enhancement Act of 2005, on May 24, 2005.62
House Resolution 810 overturns President George W. Bush's execu-
tive order barring the use of federal funds for HESCR and instead
requires the Secretary of Health and Human Services to conduct and
support such research, regardless of the date on which the stem cells
were derived from a human embryo, provided that the embryos: (1)
were donated from in vitro fertilization clinics; (2) were created for
the purpose of fertility treatment; (3) were in excess of the needs of
the individuals seeking such treatment and would otherwise be dis-
carded; and (4) were donated by such individuals with written in-
formed consent and without any financial or other inducements. 63
The Act would also require the Secretary to submit annual reports on
activities and research conducted under its auspices.64 However, un-
til this Act passes the Senate with the necessary margin of support to
sustain a Presidential veto, it will not become law.
Unfortunately, HESCR has become closely connected to the even
more controversial issue of human cloning.65 Many supporters of
HESCR have emphasized the importance of therapeutic cloning, es-
pecially after the widely-reported accomplishments of Dr. Hwang
Woo Suk and his South Korean research team, though these alleged
accomplishments are now suspect.66 Yet human cloning for thera-
peutic purposes and human cloning for reproduction have proven in-
nately entangled because advances in somatic cell nuclear transfer
("SCNT") and other techniques derived from therapeutic cloning re-
59. See id. at 99.
60. See id.
61. Poll Finds Majority of Americans Support Embryonic Stem Cell Research,
PHYs. L. WEEKLY, Sep. 7, 2005. The poll, conducted by KRC Research on behalf of the
Coalition for Pulmonary Fibrosis, found that 73% of Americans believe stem cell re-
search could one day lead to new disease treatments and cures, and that 70% support
increasing federal funding for the research. Id.
62. Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th Cong. (as
passed by House May 24, 2005).
63. H.R. 810 at § 498D(b).
64. H.R. 810 at § 498D(d).
65. See generally Michael J. Malinowski, The Impact of Current Policy and Regu-
lations on Future Stem Cell Human Health Applications, 39 NEW. ENG. L. REV. 647
(2005) (live and published symposium).
66. See supra note 46 and accompanying text.
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search have tremendous spillover potential into human cloning for
reproduction.67 The goal of many involved in embryonic stem cell re-
search is to build upon the research allegedly performed by Dr.
Hwang Woo Suk and his team-to use SCNT to clone and create
stem cells and tissue derivatives that are compatible with human do-
nors to be used in their individualized treatment and thereby avoid
issues of rejection.68
As a result, the legality of stem cell research rests in large part
upon the scope of the definition of "human cloning" used in legislation
and the existence of any exceptions for research or therapeutic clon-
ing.6 9 If a law banning human cloning draws the line at implanta-
tion, then only reproductive cloning would be prohibited. But if the
law defines cloning as occurring at nuclear transplantation, then re-
search and therapeutic cloning-including the production of stem
cells from cloned human embryos-would also be prohibited. Thus
legal limitations upon human cloning may also circumscribe HESCR
that involves SCNT.
In the U.S., several bills in Congress purport to regulate human
cloning, and each bill adopts a distinct definition. House Resolution
534, the Weldon Bill, was passed by the House of Representatives on
February 27, 2003, but never approved by the Senate.70 It defines
human cloning as occurring at the point of nuclear transplantation,
thereby proscribing research and therapeutic cloning, including the
production of stem cells from cloned human embryos. 7 ' Senate Bill
67. As explained in detail in the NAS Report, supra note 54, at 34-35, human
cloning involves several stages: removal of the nucleus from a human egg, transfer of
the nucleus from a cell of the person to be cloned into the enucleated egg, stimulation
with an electrical current in order to start cell division; this is the process known as
SCNT which was used to create Dolly and other animal species clones. See supra
notes 39-43 and accompanying text. Human cloning for reproduction involves im-
plantation of the product of SCNT into a uterus, followed by gestation and ultimately
birth of a cloned animal or possibly a person. See NAS Report, supra note 54, at 32-
33. Therapeutic cloning uses SCNT to create donor-compatible non-differentiated
cells, which then could be differentiated to create donor stem cells and tissue applica-
tions for treatment. See id. at 33.
68. See generally supra note 67.
69. See generally Bert Vogelstein et al., Please Don't Call it Cloning!, 295 Science
1237 (2002); Margaret R. McLean, What's In a Name? "Nuclear Transplantation" and
the Ethics of Stem Cell Research, 53 Hast. L.J. 1017 (2001-2002); Human Cloning and
Human Dignity: An Ethical Inquiry, Report of the President's Council on Bioethics,
July 2002, at 35-43 (see http://www.bioethics.gov/reports/cloningreport/
pcbecloningreport.pdf).
70. Human Cloning Prohibition Act of 2003, H.R. 534, 108th Cong. (as passed by
House, Feb. 27, 2003).
71. Specifically, the Weldon Bill defines "human cloning" as "human asexual re-
production, accomplished by introducing nuclear material from one or more human
somatic cells into a fertilized or unfertilized oocyte whose nuclear material has been
removed or inactivated so as to produce a living organism (at any stage of develop-
ment) that is genetically virtually identical to an existing or previously existing
human organism." H.R. 534, at §301(1). The Weldon Bill makes it unlawful to per-
form, attempt to perform, or participate in "human cloning," and it expressly prohibits
54 [Vol. 54
LEGAL LIMITATIONS ON GENETIC RESEARCH
245,72 another bill pending in the Senate that was proposed by Sena-
tor Brownback, is almost identical to the Weldon Bill and adopts the
same definition of human cloning.73
A third bill, Senate Bill 303,74 proposed by Senators Hatch, Fein-
stein, Specter, Kennedy, Harkin, and Miller, defines human cloning
in such a way as to permit stem cell research.75 Specifically, the
Hatch Bill defines "human cloning" as "implanting or attempting to
implant the product of nuclear transplantation into a uterus or the
functional equivalent of a uterus"76 and it labels the product of nu-
clear transplantation an "unfertilized blastocyst."77 The Hatch Bill
does not proscribe SCNT when performed for research or therapeutic
purposes, but instead sets forth standards regulating such research,
including: voluntary donation of oocytes with informed consent, pro-
hibition upon the purchase or sale of human oocytes or unfertilized
blastocysts, Institutional Review Board (IRB) approval of all such re-
search, prohibition of research upon unfertilized blastocysts after 14
days, and segregation of nuclear transplantation research from as-
sisted reproductive technology treatments.78
Many commissions have also addressed the issue of human clon-
ing; all have drawn a distinct line between reproductive cloning and
therapeutic cloning. The National Bioethics Advisory Commission
determined that any attempt to clone human beings at this time
would be immoral and contrary to public policy and recommended a
moratorium on reproductive cloning, but remained silent on the issue
of research cloning.79 The National Academy of Sciences concluded
the importation of any embryo or product derived from an embryo produced by human
cloning, including stem cells or other medical treatments developed outside the U.S.
H.R. 534 at §302(a), (b). The bill would punish any violation with $1 million mini-
mum fines or as much as 10 years in prison. H.R. 534 at §302(c).
72. Human Cloning Prohibition Act of 2003, S. 245, 108th Cong. (as referred to S.
Comm. on Health, Education, Labor and Pensions, Jan. 29, 2003).
73. However, Senate Bill 245 differs from House Resolution 534 in that it forbids
the importation of embryos produced by human cloning but not the importation of any
product derived from an embryo produced by human cloning, such as stem cells or
other medical treatments. S. 245 at §498D(c). However, another provision of the bill
appears to nullify this distinction by prohibiting shipping or receiving any products
derived from human cloning outside the U.S. S. 245 at §498D(b)(3). Thus this bill
presumably permits the importation of stem cells or other medical treatments pro-
duced from human cloning performed elsewhere only if it can be accomplished with-
out any shipping or receiving, for example, by transport within a living human body.
74. Human Cloning Ban and Stem Cell Research Protection Act of 2003, S. 303,
108th Cong. (as referred to S. Comm. on the Judiciary, Feb. 5, 2003).
75. The Hatch Bill makes it unlawful to perform, attempt to perform, or partici-
pate in "human cloning," as narrowly defined, S. 303 at §301(b), and it punishes viola-
tions with the same civil and criminal penalties as House Resolution 534, plus
forfeiture of any associated property, S. 303 at §301(d).
76. S. 303 at §301(a)(1).
77. S. 303 at §301(a)(6).
78. S. 303 at §499A.
79. Cloning Human Beings: Report and Recommendations of the National
Bioethics Advisory Commission, vol. 1, June 1997, at 107-110.
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that reproductive cloning should be prohibited, but research cloning
should be permitted.80 President George W. Bush's Council on
Bioethics unanimously concluded that reproductive cloning should be
prohibited, but divided on the issue of research cloning, with ten
members supporting and seven members opposing a four-year mora-
torium.8 1 And the California Advisory Committee on Human Clon-
ing (of which one of the authors was a member) unanimously
concluded in 2001, that the state should prohibit reproductive cloning
but permit research cloning subject to reasonable regulations to en-
sure informed consent, require institutional review board approval,
and limit research upon cloned human embryos to the first 14 days,
prior to development of the primitive streak.82
Ironically, despite this emerging social consensus, there may be
stronger constitutional arguments against a federal law banning re-
productive cloning than there are against a law banning research or
therapeutic cloning.83 In terms of Congressional power, if "the Con-
stitution requires a distinction between what is truly national and
what is truly local,"84 then Congress' power to regulate interstate
commerce may not extend to reproductive cloning-an activity that
may have little economic impact outside the boundaries of a particu-
lar state.85 However, Congress probably does have the power to regu-
late research cloning because it is an activity that possesses real
commercial significance. And in terms of constitutional rights, some
scholars contend that the constitutional right to reproductive auton-
omy protects reproductive cloning.86 However, the Supreme Court
has held that there is little basis for a constitutional right to use life-
saving medical treatments in the context of drug therapies not ap-
80. NAS Report, supra note 54, at 124.
81. Human Cloning and Human Dignity: An Ethical Inquiry, Report of the Presi-
dent's Council on Bioethics, July 2002 (see http://www.bioethics.gov/reports/cloningre-
port/pcbe_cloningjeport.pdf).
82. Symposium, Cloning Californians? Report of the California Advisory Commit-
tee on Human Cloning, 53 Hastings L.J. 1143 (2002).
83. See Cass R. Sunstein, Is There a Constitutional Right to Clone?, 53 Hast. L.J.
987 (2001-2002).
84. U.S. v. Morrison (2000) 529 U.S. 598, 617 (finding unconstitutional a federal
statute granting a civil remedy to victims of gender-motivated crimes).
85. See Ashutosh Bhagwat, Cloning and Federalism, 53 Hast. L.J. 1133 (2001-
2002). But see Malinowski, Choosing, supra note 14, at 179-217 (2003) (arguing that
assisted reproductive technology sector is a burgeoning business that markets itself
aggressively across state lines and country borders and, therefore, should be sub-
jected to federal regulation).
86. See John A. Robertson, Liberty, Identity, and Human Cloning, 76 Tex. L. Rev.
1371 (1998). See generally Lori B. Andrews, Is There a Right to Clone? Constitutional
Challenges to Bans on Human Cloning, 11 Harv. J.L. & Tech. 643, 666 (1998); George
J. Annas, Human Cloning: A Choice or an Echo?, 23 U. Dayton L. Rev. 247, 254
(1998); Andre P. Rose, Note, Reproductive Misconception: Why Cloning Is Not Just
Another Assisted Reproductive Technology, 48 Duke L.J. 1133, 1150 (1999); Radhika
Rao, What's So Strange About Human Cloning? 53 Hastings L.J 1007 (2002).
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proved by the FDA, and an alleged constitutional right to conduct
stem cell research probably falls into the same category. 7
III. POPULATION GENETICS
Considerable ongoing biomedical R&D centers on population ge-
netics and biobanking-the organized collection of DNA samples and
medical histories, often from sizeable populations.88 Demand for ac-
cess to human biological samples and related medical information is
at an all-time high, and rising.89 This demand is driven by explosive
bioinformatics capabilities that make it at least theoretically possible
to work through the intricacies of the human genome; we now know
that all human physiological and mental difference is attributable to
just some 30,000 or fewer expressed genes.90 With each increase in
bioinformatics capabilities, the demand for access to human biologi-
cal samples increases exponentially, and bioinformatics capabilities
appear boundless at the present time.9 ' Relative to the past, an ex-
traordinary amount of information can be drawn from any given sam-
ple, and bioinformatics enables the processing of voluminous
amounts of information from samples and medical records.92 To-
gether, bioinformatics capabilities and biobanks could prove the
means to make medical sense out of the map of the human genome.93
Domestically, many biobanking initiatives are underway. 94
Vested U.S. biobankers include hospitals, universities, commercial
87. U.S. v. Rutherford (1979) 442 U.S. 544 (holding that there is no exception to
FDA regulations for drugs for terminally ill patients).
88. See generally Symposium: Regulation of Biobanks, 33 J. L. MED. & ETHICS 1-
188 (Mark Rothstein & Bartha Knoppers eds., 2005); POPULATIONS AND GENETICS:
LEGAL AND Socio-ETHICAL PERSPECTIVES (Ed. Bartha Maria Knoppers, 2003).
89. See generally Michael J. Malinowski, Taking Genomics to the BioBank: Access
to Human Biological Samples and Medical Information, 66 LA L. REV. 43, 52 (2006).
Cf Janet Woodcock, FDA Policy on Pharmacogenomic Data in Drug Development, 66
LA L. REV 91 (2006); Paula Yoon, Risk Prediction for Common Diseases, 66 LA L. REV.
33 (2006).
90. J. Michael McGinnis, Population Health and the Influence of Medical and Sci-
entific Advances, 66 LA L. Rev. 9, 10 (2006).
91. Robert Wells, Intellectual Property/Ownership Interests, 66 LA L. Rev. 69, 70
(2006).
92. See id. at 71-72.
93. See generally A.E. Guttmacher, F.S. Collins, Welcome to the Genomic Era, 349
N. ENG. J. MED. 996-98 (2004), available at www.nejm.org; Symposium: Regulation of
Biobanks, 33 J. L. MED. & ETHICS 1-188 (Mark Rothstein & Bartha Knoppers eds.,
2005). See also L. Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs
to Fit Patients' Genetic Profiles, 43 JURIMETRICS: THE JOURNAL OF LAW, SCIENCE, AND
TECHNOLOGY 1, 4-11; (2002): Michael .J. Malinowski, Law, Policy, and Market Impli-
cations of Genetic Profiling in Drug Development, HOUSTON JOURNAL OF HEALTH LAW
& POLICY 2 (2003): 31-63, 31-43.
94. See Michael J. Malinowski, Technology Transfer in BioBanking: Credits, Deb-
its, and Population Health Futures, 33 J.L. MED. & ETHICS 54, 57 (2005).
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entities, and even a state government.95 For example, several major
hospitals, including the Harvard-affiliated Beth Israel Deaconess
Medical Center and Duke University Medical Center, are collaborat-
ing with Ardais Corporation to engage in biobanking.96 Howard Uni-
versity is biobanking to advance research for diseases with
distinguishably high incident rates among African-Americans, in-
cluding hypertension and diabetes.97 The State of Utah, in conjunc-
tion with the University of Utah and the Huntsman Cancer
Foundation, has formed GenData, a non-profit corporation, to engage
in biobanking that utilizes the rich legacy of medical record keeping
associated with Utah's Mormon community.98
Globally, biobanking already has proven a means of entry to the
genomics revolution for the populations of Iceland and Estonia.99
Several other nations are undertaking biobanking endeavors.' 00
Moreover, to explore the methodology of population genetics research
based upon ancestry, the NIH, National Center for Human Genome
Research Institute (NCHGRI), has undertaken the international
HapMap Project (HMP).' 0 This endeavor, a pilot program to explore
scientific methodology, has raised a cluster of issues, including the
scientific soundness of race-based research. 102 HMP is a collabora-
tion among scientists and funding agencies from Japan, the United
Kingdom, Canada, China, Nigeria, and the U.S.1 0 3
95. See generally D.E. Winickoff, Governing Population Genomics: Law, Bioethics,
and Biopolitics in Three Case Studies, 43 JURIMETRICS 187 (2003). See also Malinow-
ski, BioBanking, supra note 94, at 57.
96. For more information, visit the site of Ardais at http:ww.ardais.com/national
initiative/index.html. See Malinowski, BioBanking, supra note 94, at 57; Winickoff,
supra note 95, at 207.
97. A. Pollack, Big DNA Files to Help Blacks Fight Diseases, N.Y. TIMEs, May 27,
2003, at Al, A20.
98. See BARRY R. FURROW ET AL., HEALTH CARE LAW 22-23 (West 2001, Supp.
2003).
99. See generally Mylene Deschenes and Clemintine Sallee, Accountability in
Population Biobanking: Comparative Approaches, 33 J.L. MED & ETHICS 40 (2005).
100. Bartha Maria Knoppers, Biobanking: International Norms, 33 J.L. MED &
ETHICS 7 (2005); Michael J. Malinowski, Taking Genomics to the BioBank: Access to
Human Biological Samples and Medical Information, 66 LA L. REV. 43, 50 (2006).
101. Official sites with information about the HapMap Project are www.hapmap.
org and www.genome.gov. See generally Ellen Wright Clayton, Implications for Ex-
isting Law /Regulations, 66 IA L. REv. 125, 126-27 (2006); Pilar Ossorio, The Concept
of Race in Social, Cultural and Political History, and the Potential Impact of
Haplotype Mapping on the Future, 66 LA L. REV. 131 ( 2006).
102. See Sharona Hoffman, Is There a Place for "Race" as a Legal Concept?, 36 AZ
L. J. 1093, 1113-1128 (2004). See also David Rotman, Genes, Medicine, and the New
Race Debate, TECH. REV., June 2003, at 41, 48, 50.
103. Homepage: http://www.hapmap.org/. The goal of HMP is to take the concept
of familial-pedigree studies up to the population level-to compare the genetic se-
quences of different individuals to identify chromosomal regions where genetic vari-
ants are shared. HMP was commenced in October 2002, with Stage I planned for
completion this fall (fall 2005). See also Ellen Wright Clayton, Implications for Ex-
isting Law/Regulations, 66 LA L. REV. 125,126 (2006); Pilar N.Ossorio, The Concept
of Race in Social, Cultural and Political History, and the Potential Impact of
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IV. ASSISTED REPRODUCTION TECHNOLOGY (ART) AND
PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
As recognized by the President's Council on Bioethics, "The awe-
some capability to intervene at the beginning of human life through
medicine, to actually enable the creation of life and choices about
human characteristics, has burgeoned in recent years and continues
to expand at an ever-quickening pace."104 In the U.S., this capability
to intervene is realized largely through hundreds of private, self-reg-
ulated clinics that constitute a vibrant, growing economic sector gen-
erating many billions of dollars annually. 05
Assisted Reproduction Technology (ART) is popular in the U.S.,
its popularity is growing, and ART is expanding parental choice-
choice beyond whether to have children. Increasingly, ART is al-
lowing parents to choose what genetic characteristics their children
will or will not have.106 Screening embryos for selection prior to im-
plantation through preimplantation genetic diagnosis (PGD) could
expand parental choice dramatically over the next several years.' 07
Haplotype Mapping on the Future, 66 LA L. REV. 131, 133 (2006) (Special Issue). The
sample selection is deliberately based upon ancestry rather than any direct notions of
race. Nevertheless, HMP has advanced with thoughtful attention to the implications
of race-genetics connections. An ethics committee co-chaired by Dr. Bartha Knoppers
and Dr. Ellen Wright Clayton has vested tremendous effort to address implications
and develop algorithms for population genetics that potentially carry far beyond
HMP. They also have made significant personal contributions to emphasize at confer-
ences and in print that HMP is a pilot program to probe the scientific validity of an-
cestry-based population genetics. See generally Pilar N.Ossorio, The Concept of Race
in Social, Cultural and Political History, and the Potential Impact of Haplotype Map-
ping on the Future, 66 LA L. REV. 131 (2006) (Special Issue). A fundamental outcome
of this application of population genetics is pragmatic identification of ethical, legal,
social and other policy implications of the research, and pragmatic methodologies and
algorithms sensitive to those implications have been developed.
104. PRESIDENT'S COUNCIL ON BIOETHICS, REPRODUCTION AND RESPONSIBILITY: THE
REGULATION OF NEW BIOTECHNOLOGIES (Mar. 2004), available at www.bioethics.gov.;
Michael J. Malinowski, A Law-Policy Proposal to Know Where Babies Come From
During the Reproduction Revolution, - IOWA J. GENDER L. POL'Y - (forthcoming
2006). See generally ANALYTICAL SCIENCES, INC., CDC, FINAL REPORT SURVEY OF As-
SISTED REPRODUCTIVE TECHNOLOGY: EMBRYO LABORATORY PROCEDURES AND PRACTICES
(1999), available at http:/www.phppo.cd.gov/dls/pdflart/ARTsurvey.pdf; Erik
Parens & Lori P. Knowles, Reprogenetics and Public Policy: Reflections and Recom-
mendations, 33 HASTINGS CENTER REP. S1-S25 (2003) (special supplement); Malinow-
ski, Choosing, supra note 14, at 172-197. See also PAUL CARRICK, MEDICAL ETHICS IN
THE ANCIENT WORLD 99 (2001) ("[N]ever in human history has reproductive freedom
been greater: we are now providing a single person or a couple the leeway to choose
not only with whom, but when, and by what means conception will take place."). Cf.
John A. Robertson, Procreative Liberty in the Era of Genomics, 29 Am. J.L. & MED.
439 (2003).
105. See generally Parens & Knowles, Reprogenetics, supra note 104. See Malinow-
ski, Choosing, supra note 14, at 189-197.
106. See generally Parens & Knowles, Reprogenetics, supra note 104. See Malinow-
ski, Choosing, supra note 14, at 189-197.
107. See generally John A. Robertson, Debate, Extending Preimplantation Genetic
Diagnosis: the Ethical Debate, Ethical Issues in New Uses of Preimplantation Genetic
Diagnosis, 3 HUM\LAN REPRODUCTION 18, 465-71 (2003).
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"This reproduction revolution and the genomics revolution, both
ongoing and raging, are crossing into each other through use of AR
technologies."10 The nexus between these revolutions has been
termed "reprogenetics."109
The U.S. is readily distinguishable 5kmong industrialized nations
in its delegation of ART services to the medical profession and private
sector for self-regulation. 10 The Food and Drug Administration's ju-
risdiction historically has been checked to not interfere with physi-
cian discretion to practice medicine,1 ' and AR is performed as a
clinical service. 112 In fact, the Fertility Clinic Success Rate and Cer-
tification Act of 1992 (FCSRCA)"i3 expressly provides, "In developing
the certification program, the Secretary [of the Department of Health
and Human Services] may not establish any regulation, standard, or
requirement which has the effect of exercising supervision or control
over the practice of medicine in an assisted reproductive technology
program."114
Consequently, U.S. federal regulation consists almost entirely of
self-regulation through a program of voluntary reporting and certifi-
cation. 15 The federal system rests largely upon the FCSRCA, pursu-
ant to which Center for Disease Control and Prevention (CDC)
developed a model certification program for AR laboratories.11 6 The
108. See generally Parens & Knowles, Reprogenetics, supra note 104. For discus-
sion of the genomics revolution with a focus on several priority fields of study, see
Symposium Proceedings: The Genomics Revolution?: Science, Law, and Policy, 66 LA.
L. Rev. 1 (2006) (Special Issue) (live and published symposium sponsored in part by
the Department of Energy-Human Genome Project Ethical, Legal and Social Implica-
tions Program).
109. Malinowski, Reproduction Revolution, supra note 104, at - (forthcoming), cit-
ing LEE SILVER, REMAKING EDEN: CLONING AND BEYOND IN A BRAVE NEW WORLD (New
York, Avon 1997); LORI ANDREwS, THE CLONE AGE: ADVENTURES IN THE NEW WORLD
OF REPRODUCTIVE TECHNOLOGY (New York, Hering Holt, 1999); Parens & Knowles,
Reprogenetics, supra note 104.
110. See Malinowski, Choosing, supra note 14, at 179-222.
111. See 21 U.S.C. § 396 (2000) (medical device regulation); 42 U.S.C. § 1395
(2000) ("Nothing in [Medicare] shall be construed to authorize any Federal officer or
employee to exercise any supervision or control over the practice of medicine or the
manner in which medical services are provided."); 37 Fed. Reg. 16,503, 16,504 (1972)
("[I]t is clear that Congress did not intend the [FDA] to regulate or interfere with the
practice of medicine . . . .").
112. Malinowski, Choosing, supra note 14, at 180-189; Parens & Knowles,
Reprogenesis, supra note 104, at S11-S12.
113. Fertility Certification Act, Pub.L. 102-493, 106 Stat. 3146 (1992), 42 U.S.C.
263a-1 et seq.
114. 42 U.S.C. § 263a-2(i)(1) (2000).
115. See Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregu-
lated Biomedical Innovation, 55 FLA. L. REV. 603, 614-616 (2003); Malinowski, Eugen-
ics, supra note 1, at 180-197. But see Parens & Knowles, Reprogenetics, supra note
104, at S12 (stating that the FCSRCA does require clinics offering AR services to
disclose pregnancy success rates to CDC).
116. The model program is available at http://www.cdc.gov/reproductivehealth/
ART/index.htm. Supplemental sources of regulation include state regulation, practice
standards set by professional organizations, and FDA's assertion of jurisdiction over
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states have not adopted that program. CDC has contractually out-
sourced implementation of its responsibilities under the FCSRCA to
the Society for Assisted Reproductive Technology (SART) and the
American Society for Reproductive Medicine (ASRM).x 7 SART-
ASRM collects, processes, and reports the data submitted voluntarily
from members to CDC, which in turn processes that data in a stan-
dard format and issues reports annually for public dissemination.118
However, in addition to the CDC's implementation of FCSRCA, the
Federal Trade Commission (FTC) has jurisdiction to police marketing
claims and has used that authority to investigate some AR provid-
ers."19 Some states have done the same.120
V. THE IMPACT OF FDA CONTROVERSIES ON BIOTECHNOLOGY
The FDA presently is going through a difficult time. The ongoing
Cox-2 controversy and other recent events, such as the alleged failure
of Lilly to disclose troubling clinical data for Prozac even though it
has been on the market for years,121 have, at the very least, caused
many to seriously question whether the reforms to modernize the
agency during the 1990s simply went too far.122 Biotechnology was a
major beneficiary of these reforms, the mantra of which was to in-
crease responsiveness to and accelerate the review and development
of innovative biopharmaceuticals.1 23 Meaningful regulatory re-
human cloning and ooplasm transplantation. Parens & Knowles, Reprogenetics,
supra note 104, at S12.
117. For information about these organizations, visit www.sart.org and www.asrm.
org.
118. See, e.g., CDC, Report, supra note 1. These reports are issued annually, but
presently are running two years behind the governing calendar year. See generally
id.
119. Noah, Pitfalls, supra note 115, at 615 & n.49.
120. See id. at 615-616 (acknowledging that some states have enacted legislation,
and there is at least some precedent for AR patients to seek redress under general
consumer protection laws). Several commentators have called for increased consumer
protection in the field of AR. See, e.g., Lori B. Andrews & Nanette Elster, Regulating
Reproductive Technologies, 21 J. LEGAL MED. 35, 50 (2000).
121. Ken Belson, Lilly Shares Fall on Report About Prozac Documents, N.Y. TIMES,
Jan. 1, 2005, at C2; Alex Bernson, An Industry in Poor Health, N.Y. TIMES, Dec. 18,
2004, at Al; Barnaby J. Feder, The Fallout from Celebrex, N.Y. TIMEs, Dec. 18, 2004,
at Bl; Gina Kolata, A Widely Used Arthritis Drug is Withdrawn, N.Y. TIMEs, Oct. 1,
2004, at Al; Barry Meier, A Top Republican to Offer Drug Data Bill, N.Y. TIMES, Dec.
10, 2004, at C3; Anahad O'Connor & Denise Grady, Problems May Send Many Pa-
tients Back to Good Old Aspirin, N.Y. TIMEs, Dec. 18, 2004, at B1. Several major
pharmaceutical companies, in an effort to preempt government mandates, are now
posting much more clinical data voluntarily. Meier, supra.
122. This modernization refers to implementation of the Food and Drug Adminis-
tration Modernization Act of 1997. Pub. L. No. 105-115, 111 Stat. 2296 (codified
throughout 21 U.S.C.) [hereinafter "FDAMA"]. For criticism of the present regulatory
scheme and assertions of excessive drug company influence over the FDA, see gener-
ally MARCIA ANGELL, THE TRUTH ABOUT DRUG COMPANIES: How THEY DECEIVE Us
AND WHAT TO Do ABOUT IT (Random House, 2005).
123. See Michael J. Malinowski, FDA Regulation of Biotechnology Products for
Human Use, in ENCYCLOPEDIA OF ETHICAL, LEGAL AND POLICY ISSUES IN BIOTECHNOL-
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form-more government regulation, self-regulation (such as volun-
tary disclosure of clinical data now being undertaken by some
pharmaceutical companies), or some combination of the two-may be
necessary to restore the public's faith in and reliability of the
Agency:1 24
[User fees] have greatly expanded the FDA's resources, and
also created much more dialogue among the FDA, industry,
and academia.125 Ultimately, you end up in a world where a
very thick and long-standing wall was taken down between
industry and the government through regulatory reform.
While razing this wall arguably was necessary to fuel the
genomics revolution,126 accountability mechanisms must be
added in its place to ensure some regulatory checkpoints.127
Nevertheless, the FDA has demonstrated resourcefulness and
dynamism in responding to "new science" that has inundated the
Agency in recent years, and it appears that it is continuing to do
So.1 2 8 For example, the Agency is responding to the challenge of tran-
sitioning into pharmacogenomics and pharmacogenetics with
thoughtfulness and initiative.129
VI. THE NEXUs BETWEEN THE U.S. HEALTH CARE FINANCE
DILEMMA AND COMMERCIAL BIOTECHNOLOGY
According to a study conducted to quantify the rate of return on
publicly-funded research published by the U.S. Congressional Joint
OGY 221 (Thomas J. Murray & Maxwell J. Mehiman eds., 2000, John Wiley & Sons,
Inc.) (quoting the relevant provisions of FDAMA).
124. Malinowski, Future Stem Cell Human Health Applications, supra note 65, at
658-659.
125. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491
(codified throughout 21 U.S.C.) [hereinafter PDUFA I]. PDUFA I was reauthorized
(PDUFA II) in the context of FDAMA. See Prescription Drug User Fee Act of 1994,
Pub. L. No. 102-571, 106 Stat. 4491 (codified in scattered sections of 21 U.S.C. 301 et
seq.), renewed as an addendum to FDAMA. FDAMA renewed the use fee program for
five years and introduced new performance goals and other fundamental adjust-
ments. See User Fee Amendments of 2002, Pub. L. No. 107-188, 116 Stat. 687 (codi-
fied throughout 21 U.S.C.) [hereinafter PDUFA III] (extending the program to Sept.
30, 2007). See generally Foon & DRUG ADMIN., PUDFA III Five-Year Plan, available
at http://www.fda.gov/cc/pdufa3/2003plan/default.html (July 2003).
126. For support of federal technology transfer policy and practice, see generally
NAT'L INSTS. OF HEALTH, NIH Response to the Conference Report Request for a Plan to
Ensure Taxpayers' Interests are Protected, available at http://www.nih.gov/news/
070101wyden.htm (July 2001); GAO Report, supra note 4.
127. See generally Symposium, Conflicts of Interest in Clinical Research: Legal and
Ethical Issues, 8 Widener L. SYMP. J. 47, 47-73 (2001).
128. See generally, Woodcock, FDA Policy, supra note 89, at 94 (2005). See also
Malinowski, Future Stem Cell Applications, supra note 65, at 659 (addressing the tis-
sue track).
129. For an inside-the-FDA account of exactly what the agency is doing to advance
this transition, see generally Woodcock, FDA Policy, supra note 89.
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Economic Committee (JEC) in May 2000, the benefit from increased
life expectancy in the U.S. attributable to advances in health care
generates annual net gains of approximately $2.4 trillion (using 1992
dollars).o30 The JEC concluded, "If only ten percent of those in-
creases in value ($240 billion) are the result of NIH funded medical
research, it indicates a payoff of about 15 times the taxpayers' annual
NIH investment of $16 billion." 3 1 Similarly, the General Accounting
Office and NIH each have issued reports that indicate taxpayers re-
ceive a multiple return on every dollar invested in biomedical re-
search and development.132 And the U.S. has drawn an increased
share of global pharmaceutical investment in R&D. According to in-
dustry, "U.S. public policies and support for R&D have created a ma-
jor shift in dominance from Europe to the U.S.-a shift that has
included the relocation of many European pharmaceutical companies
and researchers to America."133
Nevertheless, biopharmaceuticals are entering a U.S. health care
finance system that is infamous and worsening: 45 million people are
uninsured, most of them working, and many millions more are under-
insured;134 costs are rising significantly and shifting from employers
to employees; 135 a $62 trillion shortfall is projected for Medicare, due
largely to the new prescription drug benefit;' 36 states are slashing
programs to offset their shortfalls, and the Bush Administration is
granting Medicare program waivers almost carte blanche to accom-
modate the same; and the Administration has proposed cutting $60
billion (two percent) from Medicaid over the next decade.137 The situ-
ation is disparately worse for minority groups. Both the Institutes of
130. See generally JEC, The Benefits of Medical Research, supra note 4.
131. Id.
132. See generally GAO REPORT, supra note 4; NIH, TAxPAYERS' INTERESTS, supra
note 4; NIH, TECHNOLOGIES, supra note 4.
133. PhRMA, PROFILE, supra note 1, at 20.
134. Shannon S. Venable, A Call to Action: Georgia Must Adopt New Standard of
Care, Licensure, Reimbursement and Privacy Laws for Telemedicine, 54 EMORY L.J.
1183, 1183-1184 (2005).
135. Anne D'Innocenizo, Health Care Costs Continue to Shift, CHARLOTTE OB-
SERVER (NC), Sept. 14, 2004, at 3D, available at 2005 WLNR 14458548; Glen
Singer, Survey Shows Employers Will Shift Burden of Health Benefits Increase, SUN-
SENTINEL, Aug. 27, 2004, available at 2004 WLNR 14532557; Anne D'Innocenizo,
Employers Shift Health Costs-Workers Will Take Larger Share in 2006, COM AP-
PEAL, Sept. 14, 2005, at A3; Study Shows Impact of 6 Years of Double-Digit Medical
Rate Increases, MANAGED CARE WEEKLY DIGEST 103, Mar. 28, 2005, available
at 2005 WLNR 4654487.
136. Alan Fram, Deficit Could Hit Record $477B, CINCINNATI PosT, Jan. 26, 2004,
at A2; Robert Pear and Edmund L. Andrews, White House Says Congressional Esti-
mate of New Medicare was Too Low, N.Y. TIMES, Feb. 2, 2004, at A14; Staggering
Hidden Costs of Medicare Prescriptions, New American, Feb. 23, 2004, at 9; The Medi-
care Alarm, ALBANY TIMES UNION, Apr. 5, 2004, at A6.
137. Josh Goldstein, U.S. Medicaid Cutbacks Would Hurt States Twice, PHILADEL-
PHIA INQUIRER, Feb. 8, 2005, at Cl; How Bush's Budget Goes Wrong, Bus. WEEK, Feb.
28, 2005, at 112; Robert Pear, Governors Prepare to Fight Medicaid Cuts, N.Y. TIMES,
Feb. 27, 2005, at 127.
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Medicine (1M)'3 8 and the Agency for Healthcare Research and
Quality (AHRQ) at the Department of Health and Human Services
(DHHS) have documented that minority groups in the U.S. have sig-
nificantly less access to health care, and the care they receive is of
much lower quality.139
While the public is demanding access to pharmaceuticals at
lower costs, biopharmaceuticals are almost certain to increase those
costs substantially, thereby challenging the already troubled U.S.
health care finance system.140 Genetic precision is likely to fracture
traditional disease groups, resulting in fewer patients to share the
R&D costs of developing new biopharmaceuticals, and those costs are
rising.141 Moreover, some economists are calling into question the
cost-effectiveness of individualizing medicine, including extensive
use of genetic profiling.142 Clinician acceptance and accurate use of
gene-based diagnostics and therapies poses another significant chal-
lenge.143 Presumably, biopharmaceuticals and gene-based therapies
will reduce costs when they offer cures rather than just treatments,
but that is not a present reality and may not be realized for many
years.144
VII. CONCLUSION
The overarching theme of this report is that the U.S. public, gov-
ernment, and private sectors have demonstrated commitment to bio-
technology R&D and its applications. This commitment, evident in
early completion of the HGP,145 has blossomed into a bouquet of un-
dertakings such as the HapMap Project,'146 the SNPs Consortium,
and heavy utilization of biotech in biopharmaceutical R&D. 147 And it
is resulting in at least the beginning of an actual impact on the deliv-
ery of health care, most notably through the market introduction of
biopharmaceuticals and widespread genetic profiling-in drug devel-
138. See generally Institutes of Medicine, http://www.iom.edu.
139. See generally Agency for Healthcare Research and Quality, http://www.ahrq.
gov.
140. See McGinnis, supra note 90, at 9. The level of precision introduced by bi-
opharmaceuticals will result in smaller patient groups shouldering drug R&D costs,
and this trend is likely to continue until technology evolves to actually eliminate dis-
eases rather than turning them into chronically treated conditions. See id. at 20.
141. See id. at 19.
142. See generally Jeffrey L. Moe, Commercialization Considerations (Perspectives
of Drug Manufacturers, Patients, Reimbursers, Regulators and Health Care Provid-
ers) for Individualized Diagnostic and Drug Therapies Resulting from Pharmaceoge-
nomics, 66 LA L. REV. 103, 104, 105 (2006) ( Special Issue).
143. Id. at 106.
144. See generally Woodcock, FDA Policy, supra note 89, at 101, 102 (2006) (Special
Issue).
145. See supra note 3 and accompanying text.
146. See supra notes 13, 101 and accompanying text.
147. See supra notes 6-7 and accompanying text.
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opment, human reproduction, and general health care.14 8 Applied
biotechnology now is integrating with health care, and thereby be-
coming entangled with, and in some instances exacerbating, the con-
troversies associated with the U.S. health care finance system.149
Given its deep commitment, the impact of biotechnology on the U.S.,
both economically and in terms of delivery of health care, will become
significantly greater over the next several years and well into the
foreseeable future.
148. See supra notes 7, 134, 143 and accompanying text.
149. See supra notes 134-144 and accompanying text. See also Moe, Commerciali-
zation Considerations, supra note 142, at 115.
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